O	0	4	Long
O	4	5	-
O	5	9	term
O	10	18	outcomes
O	19	21	of
O	22	30	invasive
O	31	42	ipsilateral
O	43	49	breast
O	50	55	tumor
O	56	67	recurrences
O	68	73	after
B-intervention	74	84	lumpectomy
O	85	87	in
O	88	93	NSABP
O	94	95	B
O	95	96	-
O	96	98	17
O	99	102	and
O	103	104	B
O	104	105	-
O	105	107	24
O	108	118	randomized
O	119	127	clinical
O	128	134	trials
O	135	138	for
O	139	143	DCIS
O	143	144	.

O	145	156	Ipsilateral
O	157	163	breast
O	164	169	tumor
O	170	180	recurrence
O	181	182	(
O	182	186	IBTR
O	186	187	)
O	188	190	is
O	191	194	the
O	195	199	most
O	200	206	common
O	207	214	failure
O	215	220	event
O	221	226	after
O	227	237	lumpectomy
O	238	241	for
O	242	248	ductal
O	249	258	carcinoma
O	259	261	in
O	262	266	situ
O	267	268	(
O	268	272	DCIS
O	272	273	)
O	273	274	.

O	275	277	We
O	278	287	evaluated
O	288	296	invasive
O	297	301	IBTR
O	302	303	(
O	303	304	I
O	304	305	-
O	305	309	IBTR
O	309	310	)
O	311	314	and
O	315	318	its
O	319	328	influence
O	329	331	on
O	332	340	survival
O	341	346	among
O	347	359	participants
O	360	362	in
O	363	366	two
O	367	375	National
O	376	384	Surgical
O	385	393	Adjuvant
O	394	400	Breast
O	401	404	and
O	405	410	Bowel
O	411	418	Project
O	419	420	(
O	420	425	NSABP
O	425	426	)
O	427	437	randomized
O	438	444	trials
O	445	448	for
O	449	453	DCIS
O	453	454	.

O	455	457	In
O	458	461	the
O	462	467	NSABP
O	468	469	B
O	469	470	-
O	470	472	17
O	473	478	trial
O	479	480	(
O	480	487	accrual
O	488	494	period
O	494	495	:
O	496	503	October
O	504	505	1
O	505	506	,
O	507	511	1985
O	511	512	,
O	513	515	to
O	516	524	December
O	525	527	31
O	527	528	,
O	529	533	1990
O	533	534	)
O	534	535	,
B-eligibility	536	544	patients
I-eligibility	545	549	with
I-eligibility	550	559	localized
I-eligibility	560	564	DCIS
O	565	569	were
O	570	578	randomly
O	579	587	assigned
O	588	590	to
O	591	594	the
B-control	595	605	lumpectomy
I-control	606	610	only
O	611	612	(
O	612	614	LO
O	614	615	,
O	616	617	n
O	618	619	=
B-control-participants	620	623	403
O	623	624	)
O	625	630	group
O	631	633	or
O	634	636	to
O	637	640	the
B-intervention	641	651	lumpectomy
I-intervention	652	660	followed
I-intervention	661	663	by
I-intervention	664	676	radiotherapy
O	677	678	(
O	678	681	LRT
O	681	682	,
O	683	684	n
O	685	686	=
B-intervention-participants	687	690	410
O	690	691	)
O	692	697	group
O	697	698	.

O	699	701	In
O	702	705	the
O	706	711	NSABP
O	712	713	B
O	713	714	-
O	714	716	24
O	717	723	double
O	723	724	-
O	724	731	blinded
O	731	732	,
O	733	740	placebo
O	740	741	-
O	741	751	controlled
O	752	757	trial
O	758	759	(
O	759	766	accrual
O	767	773	period
O	773	774	:
O	775	778	May
O	779	780	9
O	780	781	,
O	782	786	1991
O	786	787	,
O	788	790	to
O	791	796	April
O	797	799	13
O	799	800	,
O	801	805	1994
O	805	806	)
O	806	807	,
O	808	811	all
O	812	819	accrued
O	820	828	patients
O	829	833	were
O	834	842	randomly
O	843	851	assigned
O	852	854	to
B-control	855	858	LRT
I-control	858	859	+
I-control	860	867	placebo
O	867	868	,
O	869	870	(
O	870	871	n
O	871	872	=
B-control-participants	872	875	900
O	875	876	)
O	877	879	or
B-intervention	880	883	LRT
I-intervention	884	885	+
I-intervention	886	895	tamoxifen
O	896	897	(
O	897	900	LRT
O	901	902	+
O	903	906	TAM
O	906	907	,
O	908	909	n
O	910	911	=
B-intervention-participants	912	915	899
O	915	916	)
O	916	917	.

O	918	927	Endpoints
O	928	936	included
B-outcome-Measure	937	938	I
I-outcome-Measure	938	939	-
I-outcome-Measure	939	943	IBTR
I-outcome-Measure	943	944	,
I-outcome-Measure	945	949	DCIS
I-outcome-Measure	949	950	-
I-outcome-Measure	950	954	IBTR
O	954	955	,
B-outcome-Measure	956	969	contralateral
I-outcome-Measure	970	976	breast
I-outcome-Measure	977	984	cancers
I-outcome-Measure	985	986	(
I-outcome-Measure	986	989	CBC
I-outcome-Measure	989	990	)
O	990	991	,
B-outcome-Measure	992	999	overall
I-outcome-Measure	1000	1003	and
I-outcome-Measure	1004	1010	breast
I-outcome-Measure	1011	1017	cancer
I-outcome-Measure	1017	1018	-
I-outcome-Measure	1018	1026	specific
I-outcome-Measure	1027	1035	survival
O	1035	1036	,
O	1037	1040	and
B-outcome-Measure	1041	1049	survival
I-outcome-Measure	1050	1055	after
I-outcome-Measure	1056	1057	I
I-outcome-Measure	1057	1058	-
I-outcome-Measure	1058	1062	IBTR
O	1062	1063	.

O	1064	1070	Median
O	1071	1077	follow
O	1077	1078	-
O	1078	1080	up
O	1081	1084	was
O	1085	1088	207
O	1089	1095	months
O	1096	1099	for
O	1100	1103	the
O	1104	1105	B
O	1105	1106	-
O	1106	1108	17
O	1109	1114	trial
O	1115	1116	(
O	1116	1117	N
O	1118	1119	=
B-total-participants	1120	1123	813
O	1124	1132	patients
O	1132	1133	)
O	1134	1137	and
O	1138	1141	163
O	1142	1148	months
O	1149	1152	for
O	1153	1156	the
O	1157	1158	B
O	1158	1159	-
O	1159	1161	24
O	1162	1167	trial
O	1168	1169	(
O	1169	1170	N
O	1171	1172	=
B-total-participants	1173	1177	1799
O	1178	1186	patients
O	1186	1187	)
O	1187	1188	.

O	1189	1191	Of
O	1192	1195	490
B-outcome	1196	1200	IBTR
I-outcome	1201	1207	events
O	1207	1208	,
O	1209	1212	263
O	1213	1214	(
O	1214	1216	53
O	1216	1217	.
O	1217	1218	7
O	1218	1219	%
O	1219	1220	)
O	1221	1225	were
O	1226	1234	invasive
O	1234	1235	.

O	1236	1245	Radiation
B-outcome	1246	1253	reduced
I-outcome	1254	1255	I
I-outcome	1255	1256	-
I-outcome	1256	1260	IBTR
O	1261	1263	by
B-iv-bin-percent	1264	1266	52
I-iv-bin-percent	1266	1267	%
O	1268	1270	in
O	1271	1274	the
O	1275	1278	LRT
O	1279	1284	group
O	1285	1293	compared
O	1294	1298	with
O	1299	1301	LO
O	1302	1303	(
O	1303	1304	B
O	1304	1305	-
O	1305	1307	17
O	1307	1308	,
O	1309	1315	hazard
O	1316	1321	ratio
O	1322	1323	[
O	1323	1325	HR
O	1325	1326	]
O	1327	1329	of
O	1330	1334	risk
O	1335	1337	of
O	1338	1339	I
O	1339	1340	-
O	1340	1344	IBTR
O	1345	1346	=
O	1347	1348	0
O	1348	1349	.
O	1349	1351	48
O	1351	1352	,
O	1353	1355	95
O	1355	1356	%
O	1357	1367	confidence
O	1368	1376	interval
O	1377	1378	[
O	1378	1380	CI
O	1380	1381	]
O	1382	1383	=
O	1384	1385	0
O	1385	1386	.
O	1386	1388	33
O	1389	1391	to
O	1392	1393	0
O	1393	1394	.
O	1394	1396	69
O	1396	1397	,
O	1398	1399	P
O	1400	1401	<
O	1402	1403	.
O	1403	1406	001
O	1406	1407	)
O	1407	1408	.

O	1409	1412	LRT
O	1413	1414	+
O	1415	1418	TAM
B-outcome	1419	1426	reduced
I-outcome	1427	1428	I
I-outcome	1428	1429	-
I-outcome	1429	1433	IBTR
O	1434	1436	by
B-iv-bin-percent	1437	1439	32
I-iv-bin-percent	1439	1440	%
O	1441	1449	compared
O	1450	1454	with
O	1455	1458	LRT
O	1459	1460	+
O	1461	1468	placebo
O	1469	1470	(
O	1470	1471	B
O	1471	1472	-
O	1472	1474	24
O	1474	1475	,
O	1476	1478	HR
O	1479	1481	of
O	1482	1486	risk
O	1487	1489	of
O	1490	1491	I
O	1491	1492	-
O	1492	1496	IBTR
O	1497	1498	=
O	1499	1500	0
O	1500	1501	.
O	1501	1503	68
O	1503	1504	,
O	1505	1507	95
O	1507	1508	%
O	1509	1511	CI
O	1512	1513	=
O	1514	1515	0
O	1515	1516	.
O	1516	1518	49
O	1519	1521	to
O	1522	1523	0
O	1523	1524	.
O	1524	1526	95
O	1526	1527	,
O	1528	1529	P
O	1530	1531	=
O	1532	1533	.
O	1533	1536	025
O	1536	1537	)
O	1537	1538	.

O	1539	1542	The
B-outcome	1543	1545	15
I-outcome	1545	1546	-
I-outcome	1546	1550	year
I-outcome	1551	1561	cumulative
I-outcome	1562	1571	incidence
I-outcome	1572	1574	of
I-outcome	1575	1576	I
I-outcome	1576	1577	-
I-outcome	1577	1581	IBTR
O	1582	1585	was
B-cv-bin-percent	1586	1588	19
I-cv-bin-percent	1588	1589	.
I-cv-bin-percent	1589	1590	4
I-cv-bin-percent	1590	1591	%
O	1592	1595	for
O	1596	1598	LO
O	1598	1599	,
B-iv-bin-percent	1600	1601	8
I-iv-bin-percent	1601	1602	.
I-iv-bin-percent	1602	1603	9
I-iv-bin-percent	1603	1604	%
O	1605	1608	for
O	1609	1612	LRT
O	1613	1614	(
O	1614	1615	B
O	1615	1616	-
O	1616	1618	17
O	1618	1619	)
O	1619	1620	,
B-cv-bin-percent	1621	1623	10
I-cv-bin-percent	1623	1624	.
I-cv-bin-percent	1624	1625	0
I-cv-bin-percent	1625	1626	%
O	1627	1630	for
O	1631	1634	LRT
O	1635	1636	+
O	1637	1644	placebo
O	1645	1646	(
O	1646	1647	B
O	1647	1648	-
O	1648	1650	24
O	1650	1651	)
O	1651	1652	,
O	1653	1656	and
B-iv-bin-percent	1657	1658	8
I-iv-bin-percent	1658	1659	.
I-iv-bin-percent	1659	1660	5
I-iv-bin-percent	1660	1661	%
O	1662	1665	for
O	1666	1669	LRT
O	1670	1671	+
O	1672	1675	TAM
O	1675	1676	.

O	1677	1680	The
B-outcome	1681	1683	15
I-outcome	1683	1684	-
I-outcome	1684	1688	year
I-outcome	1689	1699	cumulative
I-outcome	1700	1709	incidence
I-outcome	1710	1712	of
I-outcome	1713	1716	all
I-outcome	1717	1730	contralateral
I-outcome	1731	1737	breast
I-outcome	1738	1745	cancers
O	1746	1749	was
B-cv-bin-percent	1750	1752	10
I-cv-bin-percent	1752	1753	.
I-cv-bin-percent	1753	1754	3
I-cv-bin-percent	1754	1755	%
O	1756	1759	for
O	1760	1762	LO
O	1762	1763	,
B-iv-bin-percent	1764	1766	10
I-iv-bin-percent	1766	1767	.
I-iv-bin-percent	1767	1768	2
I-iv-bin-percent	1768	1769	%
O	1770	1773	for
O	1774	1777	LRT
O	1778	1779	(
O	1779	1780	B
O	1780	1781	-
O	1781	1783	17
O	1783	1784	)
O	1784	1785	,
B-cv-bin-percent	1786	1788	10
I-cv-bin-percent	1788	1789	.
I-cv-bin-percent	1789	1790	8
I-cv-bin-percent	1790	1791	%
O	1792	1795	for
O	1796	1799	LRT
O	1800	1801	+
O	1802	1809	placebo
O	1810	1811	(
O	1811	1812	B
O	1812	1813	-
O	1813	1815	24
O	1815	1816	)
O	1816	1817	,
O	1818	1821	and
B-iv-bin-percent	1822	1823	7
I-iv-bin-percent	1823	1824	.
I-iv-bin-percent	1824	1825	3
I-iv-bin-percent	1825	1826	%
O	1827	1830	for
O	1831	1834	LRT
O	1835	1836	+
O	1837	1840	TAM
O	1840	1841	.

O	1842	1843	I
O	1843	1844	-
O	1844	1848	IBTR
O	1849	1852	was
O	1853	1863	associated
O	1864	1868	with
O	1869	1878	increased
B-outcome	1879	1888	mortality
I-outcome	1889	1893	risk
O	1894	1895	(
O	1895	1897	HR
O	1898	1900	of
O	1901	1906	death
O	1907	1908	=
O	1909	1910	1
O	1910	1911	.
O	1911	1913	75
O	1913	1914	,
O	1915	1917	95
O	1917	1918	%
O	1919	1921	CI
O	1922	1923	=
O	1924	1925	1
O	1925	1926	.
O	1926	1928	45
O	1929	1931	to
O	1932	1933	2
O	1933	1934	.
O	1934	1936	96
O	1936	1937	,
O	1938	1939	P
O	1940	1941	<
O	1942	1943	.
O	1943	1946	001
O	1946	1947	)
O	1947	1948	,
O	1949	1956	whereas
O	1957	1967	recurrence
O	1968	1970	of
O	1971	1975	DCIS
O	1976	1979	was
O	1980	1983	not
O	1983	1984	.

O	1985	1991	Twenty
O	1991	1992	-
O	1992	1995	two
O	1996	1998	of
O	1999	2001	39
B-outcome	2002	2008	deaths
O	2009	2014	after
O	2015	2016	I
O	2016	2017	-
O	2017	2021	IBTR
O	2022	2026	were
O	2027	2037	attributed
O	2038	2040	to
O	2041	2047	breast
O	2048	2054	cancer
O	2054	2055	.

O	2056	2061	Among
O	2062	2065	all
O	2066	2074	patients
O	2075	2076	(
O	2076	2080	with
O	2081	2083	or
O	2084	2091	without
O	2092	2093	I
O	2093	2094	-
O	2094	2098	IBTR
O	2098	2099	)
O	2099	2100	,
O	2101	2104	the
B-outcome	2105	2107	15
I-outcome	2107	2108	-
I-outcome	2108	2112	year
I-outcome	2113	2123	cumulative
I-outcome	2124	2133	incidence
I-outcome	2134	2136	of
I-outcome	2137	2143	breast
I-outcome	2144	2150	cancer
I-outcome	2151	2156	death
O	2157	2160	was
B-cv-bin-percent	2161	2162	3
I-cv-bin-percent	2162	2163	.
I-cv-bin-percent	2163	2164	1
I-cv-bin-percent	2164	2165	%
O	2166	2169	for
O	2170	2172	LO
O	2172	2173	,
B-iv-bin-percent	2174	2175	4
I-iv-bin-percent	2175	2176	.
I-iv-bin-percent	2176	2177	7
I-iv-bin-percent	2177	2178	%
O	2179	2182	for
O	2183	2186	LRT
O	2187	2188	(
O	2188	2189	B
O	2189	2190	-
O	2190	2192	17
O	2192	2193	)
O	2193	2194	,
B-cv-bin-percent	2195	2196	2
I-cv-bin-percent	2196	2197	.
I-cv-bin-percent	2197	2198	7
I-cv-bin-percent	2198	2199	%
O	2200	2203	for
O	2204	2207	LRT
O	2208	2209	+
O	2210	2217	placebo
O	2218	2219	(
O	2219	2220	B
O	2220	2221	-
O	2221	2223	24
O	2223	2224	)
O	2224	2225	,
O	2226	2229	and
B-iv-bin-percent	2230	2231	2
I-iv-bin-percent	2231	2232	.
I-iv-bin-percent	2232	2233	3
I-iv-bin-percent	2233	2234	%
O	2235	2238	for
O	2239	2242	LRT
O	2243	2244	+
O	2245	2248	TAM
O	2248	2249	.

O	2250	2258	Although
O	2259	2260	I
O	2260	2261	-
O	2261	2265	IBTR
O	2266	2275	increased
O	2276	2279	the
O	2280	2284	risk
O	2285	2288	for
O	2289	2295	breast
O	2296	2302	cancer
O	2302	2303	-
O	2303	2310	related
O	2311	2316	death
O	2316	2317	,
O	2318	2327	radiation
O	2328	2335	therapy
O	2336	2339	and
O	2340	2349	tamoxifen
O	2350	2357	reduced
O	2358	2359	I
O	2359	2360	-
O	2360	2364	IBTR
O	2364	2365	,
O	2366	2369	and
O	2370	2374	long
O	2374	2375	-
O	2375	2379	term
O	2380	2389	prognosis
O	2390	2398	remained
O	2399	2408	excellent
O	2409	2414	after
O	2415	2421	breast
O	2421	2422	-
O	2422	2432	conserving
O	2433	2440	surgery
O	2441	2444	for
O	2445	2449	DCIS
O	2449	2450	.
